Gracell Biotechnologies Co. Ltd.

May 29, 2020

Gracell Announces Two Presentations at the Annual Meeting of American Society of Clinical Oncology (ASCO)

Apr 13, 2020

Gracell to Present the First-in-human, Universal TruUCAR(TM) GC027 Therapy for Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia at the AACR Annual Meeting

Apr 03, 2020

Gracell Announces China MNPA Acceptance of Investigational New Drug Application for GC007g Cell Therapy for CD19 Positive Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia